Adam Hansard
Net worth: 444 916 $ as of 2024-04-29
Profile
Adam Hansard worked as a Senior Director of New Product Strategy at Alexion Pharmaceuticals, Inc. from 2019 to 2020.
Prior to that, he held the position of Senior Director of MS Brand Communications at Genzyme Corp.
from 2012 to 2018.
In 2018 to 2019, he served as the Vice President of Business Operations at Syntimmune, Inc. Currently, he is the Chief Commercial Officer at Applied Therapeutics, Inc. starting from 2020 until 2024.
Mr. Hansard holds a graduate degree from Jones International University and an undergraduate degree from the University of West Florida.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-09 | 105,181 ( 0.09% ) | 444 916 $ | 2024-04-29 |
Former positions of Adam Hansard
| Companies | Position | End |
|---|---|---|
| APPLIED THERAPEUTICS, INC. | Corporate Officer/Principal | 2024-04-14 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2020-02-28 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Corporate Officer/Principal | 2019-02-28 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2018-03-30 |
Training of Adam Hansard
| Jones International University | Graduate Degree |
| University of West Florida | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| APPLIED THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Adam Hansard
